NCE-1 Intelligence & Market Opportunity

Daybue

Trofinetide

Neuroprotective

Oral Solution

Daybue is the first FDA-approved oral treatment for Rett syndrome in patients 2 years of age and older. It targets neurological function to address core symptoms of the disorder.

Approval Date

10-Mar-23

NCE-1 Date

10-Mar-27

NCE Date

10-Mar-28

Commercial snapshot

Market performance & projections

Revenue ($M)

391

CAGR (%)

0.119

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

462

2027

521

2028

566

2029

613

2030

655

2031

696

2032

747

Molecule profile

Details & specifications

Molecule

Trofinetide

Innovator

ACADIA PHARMACEUTICALS INC

Dosage Form

Oral Solution

Strength

200 mg/mL

Therapeutic Category

Neuroprotective

Usage

To treat Rett syndrome in adults and children 2 years and older.

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.